Vital Therapies (VTL) Stock Rating Reaffirmed by Raymond James Financial
Vital Therapies (NASDAQ:VTL)‘s stock had its “buy” rating restated by equities research analysts at Raymond James Financial in a research note issued to investors on Tuesday.
A number of other research firms have also weighed in on VTL. BidaskClub upgraded Vital Therapies from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. Zacks Investment Research lowered Vital Therapies from a “hold” rating to a “sell” rating in a research note on Tuesday, October 31st. Finally, ValuEngine upgraded Vital Therapies from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 21st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Vital Therapies has an average rating of “Hold” and an average price target of $8.00.
Vital Therapies (NASDAQ VTL) traded up $0.15 during mid-day trading on Tuesday, reaching $4.80. The company’s stock had a trading volume of 140,900 shares, compared to its average volume of 147,791. Vital Therapies has a twelve month low of $2.25 and a twelve month high of $6.50.
Vital Therapies (NASDAQ:VTL) last released its earnings results on Wednesday, October 25th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. During the same period in the previous year, the business posted ($0.32) earnings per share. sell-side analysts expect that Vital Therapies will post -1.26 EPS for the current year.
In other news, Director Muneer A. Satter purchased 130,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The shares were purchased at an average price of $4.01 per share, for a total transaction of $521,300.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Muneer A. Satter purchased 50,000 shares of the business’s stock in a transaction dated Friday, September 8th. The shares were purchased at an average price of $3.53 per share, for a total transaction of $176,500.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 190,000 shares of company stock worth $737,800. Insiders own 32.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP purchased a new position in Vital Therapies in the third quarter valued at about $116,000. JPMorgan Chase & Co. grew its stake in Vital Therapies by 1,985.3% in the third quarter. JPMorgan Chase & Co. now owns 25,462 shares of the company’s stock valued at $123,000 after purchasing an additional 24,241 shares during the last quarter. New York State Common Retirement Fund purchased a new position in Vital Therapies in the third quarter valued at about $213,000. Dowling & Yahnke LLC purchased a new position in Vital Therapies in the third quarter valued at about $252,000. Finally, Goldman Sachs Group Inc. grew its stake in Vital Therapies by 1.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock valued at $258,000 after purchasing an additional 1,157 shares during the last quarter. Institutional investors own 24.35% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/vital-therapies-vtl-stock-rating-reaffirmed-by-raymond-james-financial/1747796.html.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.